Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Autoimmune disorder, Granuloma annulare
Clinical narrative: Autoimmune skin condition; had newbreakouts of annulare granulomas; This spontaneous case was reported by an other health care professional and describes the occurrence of AUTOIMMUNE DISORDER (Autoimmune skin condition) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for Product used for unknown indication: TDAP on 16-Apr-2008, TDAP on 16-Apr-2008 and TDAP on 16-Apr-2008. Past adverse reactions to the above products included Local reaction with TDAP; Swelling arm with TDAP; and Tachycardia with TDAP. Concurrent medical conditions included Fibromyalgia and Hypersensitivity reaction (which required half doses of many medications). Concomitant products included NALTREXONE, PARACETAMOL (TYLENOL ARTHRITIS) and ALPRAZOLAM for an unknown indication.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced AUTOIMMUNE DISORDER (Autoimmune skin condition) (seriousness criterion medically significant) and GRANULOMA ANNULARE (had newbreakouts of annulare granulomas). At the time of the report, AUTOIMMUNE DISORDER (Autoimmune skin condition) had not resolved and GRANULOMA ANNULARE (had newbreakouts of annulare granulomas) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered AUTOIMMUNE DISORDER (Autoimmune skin condition) and GRANULOMA ANNULARE (had newbreakouts of annulare granulomas) to be related.    The patient had new breakouts of annulare granulomas which dermatologist treated with steroid injections (unspecified). The patient was advised to avoid another mrna 1273 booster by doctors (dose number in series 1). However, they suggested a J and J might be a better choice. Treatment medication not reported. This is a spontaneous case concerning  a 75-year-old, female patient with Concurrent medical conditions of Fibromyalgia and Hypersensitivity reaction, who experienced the unexpected serious event Autoimmune disorder and unexpected non-serious event of Granuloma Annulare. The events occurred on an unknown day, since the date of vaccination and date of adverse event started, it is difficult to determine which dose caused the events.  The reporter assessed the events as related to the product. The Concurrent medical conditions of Fibromyalgia and Hypersensitivity reaction remains a confounder. The events outcome was unknown. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.; Sender's Comments: This is a spontaneous case concerning  a 75-year-old, female patient with Concurrent medical conditions of Fibromyalgia and Hypersensitivity reaction, who experienced the unexpected serious event Autoimmune disorder and unexpected non-serious event of Granuloma Annulare. The events occurred on an unknown day, since the date of vaccination and date of adverse event started, it is difficult to determine which dose caused the events.  The reporter assessed the events as related to the product. The Concurrent medical conditions of Fibromyalgia and Hypersensitivity reaction remains a confounder. The events outcome was unknown. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.